Scientists at the Pritzker School of Molecular Engineering (PME) at the University of Chicago say they have discovered a general property for understanding how immune cells sense and respond to microbial signals. By studying how molecules impact these cells, they found that while the effect of a single molecule does not predict the effect of two molecules together, the complexity stops there. In fact, the effect of singles and pairs of molecules can be used to predict how triplets of molecules work.
The study, “Pairwise Stimulations of Pathogen-Sensing Pathways Predict Immune Responses to Multi-adjuvant Combinations,” led by Nicolas Chevrier, PhD, assistant professor, and published in Cell Systems, led to a more effective cancer immunotherapy in mice and could lead to more effective vaccines for both existing and novel viruses, note the researchers.
“The immune system makes decisions in response to combinations of multiple microbial inputs. We do not understand the combinatorial logic governing how higher-order combinations of microbial signals shape immune responses,” write the investigators.
“Here, using coculture experiments and statistical analyses, we discover a general property for the combinatorial sensing of microbial signals, whereby the effects of triplet combinations of microbial signals on immune responses can be predicted by combining the effects of single and pairs. Mechanistically, we find that singles and pairs dictate the information signaled by triplets in mouse and human DCs at the levels of transcription, chromatin, and protein secretion.”
“We exploit this simplifying property to develop cell-based immunotherapies prepared with adjuvant combinations that trigger protective responses in mouse models of cancer. We conclude that the processing of multiple input signals by innate immune cells is governed by pairwise effects, which will inform the rationale combination of adjuvants to manipulate immunity.”
Innate immune cells have receptors that recognize molecules from foreign pathogens. To fight off bacteria or viruses, those cells make decisions in response to complex combinations of inputs from those molecules. Though researchers have studied singular pathways, how these pathways work together is still not well understood.
Chevrier and his collaborators set out to better understand how cells integrate multiple signals into a response. Not only would it help answer a basic fundamental question of biology, it would also help design vaccines that use adjuvants, molecules that help modulate the immune system and enhance its response.
Though just a few vaccines currently use them, adjuvants might be the key to developing new kinds of vaccines. Right now, FDA-approved adjuvants target only one or two of the cell’s receptors. If researchers could find the right combination to target more, vaccines could become more effective.
Chevrier and his collaborators used adjuvants to stimulate immune cells in petri dishes to figure out what happens when single molecules, pairs of molecules, and triplets of molecules are used. If the results were additive, the effects of one molecule and the effects of another molecule would, when combined, remain the same. Researchers found that wasn’t the case. Two molecules combined together led to different effects than each had singularly.
But they did find that the effect of single molecules and pairs of molecules could accurately predict what happened with triplets of molecules.
“It could have been infinitely complex, but it’s not,” Chevrier said. “We are the first to show you can predict higher-order effects across immune pathways with very simple models.”
To prove their theory, the researchers injected cells conditioned with certain combinations of adjuvants—creating a specific cancer immunotherapy treatment—in a mouse model with tumors. The response was potent: the tumors grew five to ten times less in treated mice versus untreated mice.
“That was very encouraging,” added Chevrier. “Now we need to better understand the mechanisms of why this worked so well.”
The researchers also hope to search for new combinations of adjuvants that have equally strong effects and eventually mount a clinical trial in humans.
“Now that we can predict the effects of multiple adjuvants with little data and a simple model, we need to extend this knowledge to the design of vaccines against both new and old threats,” said Chevrier.
